Diet quality indices and changes in cognition during chemotherapy
- PMID: 36544032
- PMCID: PMC10127432
- DOI: 10.1007/s00520-022-07513-5
Diet quality indices and changes in cognition during chemotherapy
Abstract
Purpose: No evidence-based prevention strategies currently exist for cancer-related cognitive decline (CRCD). Although patients are often advised to engage in healthy lifestyle activities (e.g., nutritious diet), little is known about the impact of diet on preventing CRCD. This secondary analysis evaluated the association of pre-treatment diet quality indices on change in self-reported cognition during chemotherapy.
Methods: Study participants (n = 96) completed the Block Brief Food Frequency Questionnaire (FFQ) before receiving their first infusion and the PROMIS cognitive function and cognitive abilities questionnaires before infusion and again 5 days later (i.e., when symptoms were expected to be their worst). Diet quality indices included the Dietary Approaches to Stop Hypertension (DASH), Alternate Mediterranean Diet (aMED), and a low carbohydrate diet index and their components. Descriptive statistics were generated for demographic and clinical variables and diet indices. Residualized change models were computed to examine whether diet was associated with change in cognitive function and cognitive abilities, controlling for age, sex, cancer type, treatment type, depression, and fatigue.
Results: Study participants had a mean age of 59 ± 10.8 years and 69% were female. Although total diet index scores did not predict change in cognitive function or cognitive abilities, higher pre-treatment ratio of aMED monounsaturated/saturated fat was associated with less decline in cognitive function and cognitive abilities at 5-day post-infusion (P ≤ .001).
Conclusions: Higher pre-treatment ratio of monounsaturated/saturated fat intake was associated with less CRCD early in chemotherapy. Results suggest greater monounsaturated fat and less saturated fat intake could be protective against CRCD during chemotherapy.
Keywords: Cancer; Cancer survivors; Chemo-brain; Chemotherapy; Cognition; Diet; Nutrition.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Dr. Jim is a consultant for Janssen Scientific Affairs and Merck. She has grant funding from Kite Pharma. Dr. Li reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Bayer Healthcare, Coherus BioSciences, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon Pharmaceuticals, Merck, MiNA Therapeutics, QED Therapeutics, Servier, Sun Pharma, Taiho Pharmaceutical, and TerSera Therapeutics. Dr. Brownstein served as an ad-hoc grant reviewer in 2020 for the American Cancer Society, for which she received sponsored travel during the review meeting and a stipend of $300. She also received $500 from the Statistical Consulting Section of the American Statistical Association (ASA) for Best Paper Award at the 2019 Joint Statistical Meetings, a Michael Kutner/ASA Junior Faculty Travel Award of US $946.60 to attend the 2018 Summer Research Conference of the Southern Regional Council on Statistics, and travel support of US $708.51 plus a registration waiver from the ASA to attend and chair a session for the 2017 Symposium on Statistical Inference. Dr. Extermann is a consultant for Aileron and Alnylam, and received honoraria from OncLive and the American Porphyria Foundation. Dr. Rotroff has an equity stake in Clarified Precision Medicine, LLC, has received research support from Novo Nordisk, and consulting honoraria from Pharmazaam, LLC. Dr. Rotroff owns intellectual property related to the treatment of type 2 diabetes, chronic liver disease, liver, and blood cancers.
Figures
References
-
- Joly F et al. (2015) Impact of cancer and its treatments on cognitive function: advances in research from the paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manage 50(6):830–841 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
